Paul Wales · Cost-utility analysis of 4% tetrasodium ethylenediaminetetraacetic acid, taurolidine, and heparin lock to prevent central line-associated bloodstream infections in children with intestinal failure.

Follow

From Dr. Paul Wales

Article1 min read·Published Nov 2026

Cost-utility analysis of 4% tetrasodium ethylenediaminetetraacetic acid, taurolidine, and heparin lock to prevent central line-associated bloodstream infections in children with intestinal failure.

Part of Pharmacologic Therapies 5 items

pubmed.ncbi.nlm.nih.gov

Cost-utility analysis of 4% tetrasodium ethylenediaminetetraacetic acid, taurolidine, and heparin lock to prevent central line-associated bloodstream infections in children with intestinal failure.

Paul Wales

Central line-associated bloodstream infections (CLABSI) are a serious complication in children with intestinal failure. This study assessed the incremental costs of 4% tetrasodium ethylenediaminetetraacetic acid (EDTA) compared with taurolidine lock and heparin lock per quality-adjusted life-year (QALY) gained in children with intestinal failure from the healthcare payer and societal perspective. …

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Nov 2026 · 1 min read

In brief

In brief

Economic evaluation comparing three catheter lock solutions (4% EDTA, taurolidine, heparin) for preventing central line infections in pediatric intestinal failure patients. Analysis examines cost per quality-adjusted life-year from healthcare and societal perspectives to inform clinical decision-making.

Written by the GCMD Library team from the article.

Paul Wales

Central line-associated bloodstream infections (CLABSI) are a serious complication in children with intestinal failure. This study assessed the incremental costs of 4% tetrasodium ethylenediaminetetraacetic acid (EDTA) compared with taurolidine lock and heparin lock per quality-adjusted life-year (QALY) gained in children with intestinal failure from the healthcare payer and societal perspective. …

Read it at the source ↗

Try

Intelligent Search· scoped to this article · not medical adviceSearch the whole library →

More in this field

Dive deeper → Pharmacologic Therapies (5 items)

Association between 4%-tetrasodium EDTA and sepsis in neonatal piglets: A retrospective cohort study.

Paul Wales · Published Nov 2026

Teduglutide's Impact on Short Bowel Syndrome: Reducing TPN Needs and Promoting Rehabilitation w/ Dr. Paul Wales

32 s · Published Oct 2026

Clinical outcomes of teduglutide therapy in children with short bowel syndrome-associated intestinal failure: A single-center experience

Michael Helmrath · Published Jun 2026

Cost-utility analysis of teduglutide compared to standard care in weaning parenteral nutrition support in children with short bowel syndrome

Paul Wales · Published Oct 2023

More from this author

Dive deeper → Dr. Paul Wales

Use of a combined transient elastography and biochemical strategy to determine liver fibrosis in pediatric intestinal failure.

Paul Wales · Published Nov 2026

The impact of multi-disciplinary intestinal rehabilitation programs on the outcome of pediatric patients with intestinal failure: a systematic review and meta-analysis.

Paul Wales · Published Nov 2026

"Line care governs our entire world": Understanding the experience of caregivers of children with intestinal failure receiving long-term parenteral nutrition.

Paul Wales · Published Nov 2026

Intestinal transplantation in children: current status.

Paul Wales · Published Nov 2026

Surgical Management and Intestinal Rehabilitation in Short Bowel Syndrome

Paul Wales · 71 min · Published Nov 2026

Predictors of Social-Emotional Development and Adaptive Functioning in School-Age Children with Intestinal Failure.

Paul Wales · Published Nov 2026